JP2016536361A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536361A5
JP2016536361A5 JP2016551017A JP2016551017A JP2016536361A5 JP 2016536361 A5 JP2016536361 A5 JP 2016536361A5 JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016536361 A5 JP2016536361 A5 JP 2016536361A5
Authority
JP
Japan
Prior art keywords
seq
antibody
hours
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/073612 external-priority patent/WO2015067570A2/en
Publication of JP2016536361A publication Critical patent/JP2016536361A/ja
Publication of JP2016536361A5 publication Critical patent/JP2016536361A5/ja
Pending legal-status Critical Current

Links

JP2016551017A 2013-11-06 2014-11-03 Cd33抗体及び脱メチル剤を含む医薬配合物 Pending JP2016536361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191839 2013-11-06
EP13191839.3 2013-11-06
PCT/EP2014/073612 WO2015067570A2 (en) 2013-11-06 2014-11-03 Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

Publications (2)

Publication Number Publication Date
JP2016536361A JP2016536361A (ja) 2016-11-24
JP2016536361A5 true JP2016536361A5 (OSRAM) 2017-12-14

Family

ID=49518850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551017A Pending JP2016536361A (ja) 2013-11-06 2014-11-03 Cd33抗体及び脱メチル剤を含む医薬配合物

Country Status (4)

Country Link
US (2) US20150125447A1 (OSRAM)
EP (1) EP3066125A2 (OSRAM)
JP (1) JP2016536361A (OSRAM)
WO (1) WO2015067570A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EA035979B1 (ru) 2014-09-09 2020-09-08 Янссен Байотек, Инк. Варианты комбинированной терапии анти-cd38 антителами
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
HRP20240338T1 (hr) * 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
NZ739503A (en) * 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP4516319A3 (en) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US12213801B2 (en) 2020-10-02 2025-02-04 Cilag Gmbh International Surgical visualization and particle trend analysis system
US11992372B2 (en) 2020-10-02 2024-05-28 Cilag Gmbh International Cooperative surgical displays
US11830602B2 (en) 2020-10-02 2023-11-28 Cilag Gmbh International Surgical hub having variable interconnectivity capabilities
US11963683B2 (en) 2020-10-02 2024-04-23 Cilag Gmbh International Method for operating tiered operation modes in a surgical system
US12472032B2 (en) 2020-10-02 2025-11-18 Cilag Gmbh International Monitoring of user visual gaze to control which display system displays the primary information
US11748924B2 (en) 2020-10-02 2023-09-05 Cilag Gmbh International Tiered system display control based on capacity and user operation
US12064293B2 (en) 2020-10-02 2024-08-20 Cilag Gmbh International Field programmable surgical visualization system
US12016566B2 (en) 2020-10-02 2024-06-25 Cilag Gmbh International Surgical instrument with adaptive function controls
US11877897B2 (en) 2020-10-02 2024-01-23 Cilag Gmbh International Situational awareness of instruments location and individualization of users to control displays
US12484897B2 (en) 2020-10-02 2025-12-02 Cilag Gmbh International Surgical instrument with adaptive configuration control
US11672534B2 (en) 2020-10-02 2023-06-13 Cilag Gmbh International Communication capability of a smart stapler
CN116948029A (zh) 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент

Similar Documents

Publication Publication Date Title
JP2016536361A5 (OSRAM)
AU2013327116B2 (en) Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
JP2015534579A5 (OSRAM)
JP2015534578A5 (OSRAM)
JP2015532292A5 (OSRAM)
JP2014533279A5 (OSRAM)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2018534933A5 (OSRAM)
JP2018070648A5 (OSRAM)
JP2016094424A5 (OSRAM)
JP2016507470A5 (OSRAM)
JP2017514795A5 (OSRAM)
JP2016501892A5 (OSRAM)
JP2010520290A5 (OSRAM)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2011046732A5 (OSRAM)
JP2019536806A5 (OSRAM)
JP2014511179A5 (OSRAM)
JP2015534580A5 (OSRAM)
JP2017528476A5 (OSRAM)
JP2014205674A5 (OSRAM)
JP2016502504A5 (OSRAM)
JP2017529838A5 (OSRAM)
JP2014530215A5 (OSRAM)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a